BlackRock pushes Exscientia Series C to $100M as AI biotech boom continues
The jury’s still out on whether the first wave of AI companies can significantly change drug development, but investors are increasingly buying into the hype.
Exscientia, the decade-old UK machine learning outfit, announced Thursday that they’ve expanded their Series C, first announced in May, from $60 million to $100 million. The expansion most notably includes BlackRock, the private equity firm that has been wading deeper and deeper into biotech. They now join Novo Holdings, Bristol Myers Squibb and others among the company’s most recent backers.